Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
MWN-AI** Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced the completion of patient enrollment in its Phase 2 clinical study evaluating NGC-Cap, a novel combination treatment for advanced or metastatic breast cancer. The study's design involves comparing NGC-Cap, a proprietary combination of PCS6422 and capecitabine, against capecitabine monotherapy. A total of 20 patients have enrolled, each having undergone multiple prior cancer therapies. The interim analysis will assess the safety and efficacy of NGC-Cap compared to standard capecitabine treatment, with results expected in the first quarter of 2026.
George Ng, CEO of Processa Pharmaceuticals, emphasized the significance of this milestone, as it allows for the evaluation of whether NGC-Cap can provide improved outcomes over traditional treatments for patients with advanced cancer. The study includes specific criteria such that patients must have had at least one prior treatment, with a median of two to three regimens, highlighting the targeted patient population facing limited options.
NGC-Cap treatment involves administering a single dose of PCS6422 the day before starting capecitabine, potentially enhancing the formation of metabolites that kill cancerous cells while minimizing harmful side effects. The interim analysis will not only compare the safety profiles of both treatment arms but also explore optimal dosage options and possible adjustments to the overall study sample size based on preliminary findings. Dr. David Young, the President of Research and Development, noted that these initial data will be key in steering the future path for maximizing NGC-Cap's therapeutic potential.
Processa Pharmaceuticals aims to develop safer, more effective cancer therapies by modifying existing treatments, maintaining their cancer-fighting capabilities while enhancing patient tolerability.
MWN-AI** Analysis
As a financial analyst, the recent announcement from Processa Pharmaceuticals regarding the completion of patient enrollment for the interim analysis of their Phase 2 NGC-Cap breast cancer study presents a pivotal moment for investors. With the formal interim analysis set to deliver safety and efficacy data in Q1 2026, stakeholders should be prepared for significant market movements that could arise from these findings.
Processa's innovative approach combines PCS6422 with capecitabine, aiming to enhance the drug's effectiveness while reducing adverse side effects. This differentiation sets Processa apart in the crowded oncology market. Given the complexity of breast cancer therapies and the evolving landscape of treatment options, if NGC-Cap demonstrates meaningful improvement over the traditional capecitabine monotherapy, it could position Processa as a leader in the next generation of cancer therapeutics.
Investors should closely monitor the interim analysis results, which will not only evaluate safety and preliminary efficacy but also inform potential modifications to the study’s design and sample size. Any positive signals from this analysis could lead to increased investor confidence, potentially resulting in a surge in stock performance. Conversely, unfavorable results may lead to volatility, which investors must be ready to navigate.
The company's strategy of developing modified versions of existing therapies helps mitigate risk compared to fully novel treatments, but it retains exposure to significant upside if the trials yield favorable outcomes. Furthermore, Processa is actively pursuing partnerships beyond oncology, which may unlock additional avenues for growth and revenue.
Given these factors, maintaining a watchful eye on upcoming announcements and market reactions in the early months of 2026 is advisable for investors looking to capitalize on Processa's developments in the oncology space. It could be a critical juncture for the firm, marking either a breakthrough or a setback in its trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Interim safety and efficacy data to be reported in Q1
VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa’s proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer.
“This is an important milestone because it allows us to assess whether NGC-Cap can demonstrate a meaningful improvement over capecitabine monotherapy in both safety and efficacy for patients who have already undergone multiple prior cancer treatments.,” said George Ng, Chief Executive Officer of Processa Pharmaceuticals.
Study Design and Patient Characteristics
The randomized, FDA-recommended Phase 2 study is designed to compare NGC-Cap (Arm A) with standard-of-care capecitabine monotherapy (Mono-Cap, Arm C) in patients with advanced or metastatic breast cancer. Patients enrolled in the study were required to have received at least one prior cancer treatment, with a median of two to three prior treatment regimens across the enrolled population.
NGC-Cap consists of a single dose of PCS6422 administered one day prior to capecitabine, followed by capecitabine at 150 mg twice daily for seven days on treatment and seven days off. The Mono-Cap arm consists of capecitabine administered at 1,000 mg/m² twice daily for 14 days followed by seven days off treatment.
PCS6422 is designed to re-engineer capecitabine metabolism by increasing the formation of cancer-killing metabolites (anabolites) while decreasing the formation of metabolites associated primarily with side effects (catabolites).
Formal Interim Analysis Objectives
The formal interim analysis will compare safety and preliminary efficacy outcomes between the NGC-Cap and Mono-Cap treatment arms and is expected to be completed in the first quarter of 2026. Key objectives of the interim analysis include:
- Evaluating the comparative safety and efficacy of NGC-Cap versus Mono-Cap
- Determining whether a higher or lower dose of NGC-Cap should be added as a third study arm
- Assessing whether the overall sample size of the Phase 2 study should be adjusted based on interim findings
“The interim analysis is designed to evaluate early signals of clinical benefit and to guide potential optimization of dose selection and overall study design,” said Dr. David Young, President of Research and Development at Processa. “These data will be critical as we determine the most appropriate path forward to maximize the therapeutic potential of NGC-Cap.”
About NGC-Cap (PCS6422+Capecitabine)
NGC-Cap is Processa’s lead oncology asset and a key component of its Next Generation Cancer (NGC) platform. When administered, NGC-Cap is designed to increase systemic exposure to active cancer-killing anabolite metabolites while reducing formation of toxic catabolite metabolites, potentially improving the therapeutic index of Capecitabine-based therapy.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path. In addition to its core oncology programs, Processa is actively pursuing strategic partnerships for non-oncology assets to unlock additional value.
For more information, visit our website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
PCSA@redchip.com
FAQ**
What specific safety outcomes will Processa Pharmaceuticals Inc. PCSA focus on in the interim analysis comparing NGC-Cap to Mono-Cap, and how will these results influence future dosing strategies?
How does Processa Pharmaceuticals Inc. PCSA plan to evaluate preliminary efficacy outcomes of NGC-Cap versus capecitabine monotherapy during the interim analysis, and what metrics will be used?
In what ways could the findings from the interim analysis lead Processa Pharmaceuticals Inc. PCSA to adjust the overall sample size of the Phase 2 study if necessary?
What are the expectations for identifying early clinical benefit during the interim analysis of NGC-Cap at Processa Pharmaceuticals Inc. PCSA, and how might this affect the drug's development pathway?
**MWN-AI FAQ is based on asking OpenAI questions about Processa Pharmaceuticals Inc. (NASDAQ: PCSA).
NASDAQ: PCSA
PCSA Trading
4.07% G/L:
$2.81 Last:
4,745 Volume:
$2.65 Open:
